Studies have revealed that patients with gastrointestinal tract tumors, such as colorectal, esophageal, and GC, who exhibit elevated levels of Prevotella/Bacteroides respond more favorably to anti-PD-1/PD-L1 therapy. Here, CD274 is linked to gastric cancer.